National Psoriasis Foundation Partners with National Institutes of Health and Others to Identify and Map Key Biological Pathways That Drive Immune-Mediated and Autoimmune Diseases

Portland, Ore., Dec. 17, 2021 – Last week, the National Institutes of Health (NIH) and The Foundation of the NIH (FNIH) announced the launch of a transformative program that will impact the community of people who experience psoriatic disease, a chronic immune-mediated disease associated with systemic inflammation.

The National Psoriasis Foundation (NPF) is proud to announce its partnership in this public-private endeavor, which is intended to accelerate the rate at which new treatments and interventions for those with psoriatic disease – as well as other immune-mediated or autoimmune diseases – are identified and developed.

The goal of the Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) Program is to investigate how cells of the immune system interact with tissue to drive inflammation and immune-mediated and autoimmune diseases. According to the FNIH, this program “will advance our understanding of key disease pathways using new tools to map in three-dimensions how cell types, cell states, and cell-to-cell interactions network to cause inflammation, abnormal function, and tissue injury. The resulting data will accelerate our understanding of the fundamental mechanisms and causes of [immune-mediated and] autoimmune disease, allow more informed selection of patients for clinical trials, and generate new targets for drug development.”

“As the Accelerating Medicines Partnership expands to include psoriasis and psoriatic arthritis, NPF looks forward to the answers that this robust initiative may generate,” said Stacie Bell, Ph.D., NPF Chief Scientific and Medical Officer. “This next generation public-private partnership will enable discovery of new mechanisms and targets for novel intervention and treatment development, as well as an enhanced disease understanding for earlier diagnosis and improved management by leveraging collaboration and technical innovation. As the voice of the psoriatic disease community for over five decades, NPF joins with excitement about the possibilities that AMP® AIM holds to achieve the vision of a life free of psoriatic disease and the associated burdens."

Learn more about AMP® AIM 2.0 and the potential for accelerating the development of new treatments and intervention in the FNIH AMP® AIM 2.0 press release.

Serving the community of people impacted by psoriatic disease for more than 50 years with patient support, advocacy, research, education, and funding, the National Psoriasis Foundation is the leading nonprofit representing individuals with psoriasis and psoriatic arthritis. The mission of NPF is to drive efforts to cure psoriatic disease and improve the lives of more than 8 million individuals in the United States affected by this chronic immune-mediated disease. As part of that effort, NPF created the Patient Navigation Center to offer personalized assistance to everyone with psoriasis or psoriatic arthritis. In recent years, NPF has funded more than $28 million in research grants and fellowships that help drive discoveries that may lead to more and better treatments and ultimately a cure. Learn more at psoriasis.org.

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity Navigator

Copyright © 1996-2021 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.